Dexamethasone decreases xenograft response to paclitaxel through inhibition of tumor cell apoptosis

Cancer Biology and Therapy

Volumn 5, Issue 8, 2006, Pages 933-940

  Pang, Diana ^a   Kocherginsky, Masha ^a   Krausz, Thomas ^a   Kim, So Young ^a   Conzen, Suzanne D ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Apoptosis; Breast cancer; Dexamethasone; Glucocorticoids; Paclitaxel; Q RT PCR; Xenograft

Indexed keywords

CELL CYCLE PROTEIN; DEXAMETHASONE; PACLITAXEL; PROTEIN BID; PROTEIN MKP 1; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CANCER CHEMOTHERAPY; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; DRUG INHIBITION; DRUG MECHANISM; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; NONHUMAN; UPREGULATION;

EID: 33751167213     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.5.8.2875     Document Type: Article

References (60)

1. McKay LI, Cidlowski JA. Molecular control of immune/inflammatory responses: Interactions between nuclear factor-kappa B and steroid receptor-signaling pathways. Endocr Rev 1999; 20:435-59.
2. Amsterdam A, Sasson R. The anti-inflammatory action of glucocorticoids is mediated by cell type specific regulation of apoptosis. Mol Cell Endocrinol 2002; 189:1-9.
3. Messmer UK, Pereda-Fernandez C, Manderscheid M, Pfeilschifter J. Dexamethasone inhibits TNF-alpha-induced apoptosis and IAP protein downregulation in MCF-7 cells. Br J Pharmacol 2001; 133:467-76.
4. Buchmann A, Willy C, Buenemann CL, Stroh C, Schmiechen A, Schwarz M. Inhibition of transforming growth factor beta1-induced hepatoma cell apoptosis by liver tumor promoters: Characterization of primary signaling events and effects on CPP32-like caspase activity. Cell Death Differ 1999; 6:190-200.
5. Yamamoto M, Fukuda K, Miura N, Suzuki R, Kido T, Komatsu Y. Inhibition by dexamethasone of transforming growth factor beta1-induced apoptosis in rat hepatoma cells: A possible association with Bcl-xL induction. Hepatology 1998; 27:959-66.
6. Gascoyne DM, Kypta RM, Vivanco MM. Glucocorticoids inhibit apoptosis during fibrosarcoma development by transcriptionally activating Bcl-xL. J Biol Chem 2003; 278:18022-9.
7. Hammer S, Sauer B, Spika I, Schraut C, Kleuser B, Schafer-Korting M. Glucocorticoids mediate differential anti-apoptotic effects in human fibroblasts and keratinocytes via sphingosine-1-phosphate formation. J Cell Biochem 2004; 91:840-51.
8. Baumann S, Dostert A, Novac N, Bauer A, Schmid W, Fas SC, Krueger A, Heinzel T, Kirchhoff S, Schutz G, Krammer PH. Glucocorticoids inhibit activation-induced cell death (AICD) via direct DNA-dependent repression of the CD95 ligand gene by a glucocorticoid receptor dimer. Blood 2005; 106:617-25.
9. Cui H, Sherr DH, el-Khatib M, Matsui K, Panka DJ, Marshak-Rothstein A, Ju ST. Regulation of T-cell death genes: Selective inhibition of FasL- but not Fas-mediated function. Cell Immunol 1996; 167:276-84.
10. D'Adamio F, Zollo O, Moraca R, Ayroldi E, Bruscoli S, Bartoli A, Cannarile L, Migliorati G, Riccardi C. A new dexamethasone-induced gene of the leucine zipper family protects T lymphocytes from TCR/CD3-activated cell death. Immunity 1997; 7:803-12.
11. Iseki R, Mukai M, Iwata M. Regulation of T lymphocyte apoptosis. Signals for the antagonism between activation- and glucocorticoid-induced death. J Immunol 1991; 147:4286-92.
12. Wang R, Zhang L, Zhang X, Moreno J, Luo X, Tondravi M, Shi Y. Differential regulation of the expression of CD95 ligand, receptor activator of nuclear factor-kappa B ligand (RANKL), TNF-related apoptosis-inducing ligand (TRAIL), and TNF-alpha during T cell activation. J Immunol 2001; 166:1983-90.
13. Webster JC, Huber RM, Hanson RL, Collier PM, Haws TF, Mills JK, Burn TC, Allegretto EA. Dexamethasone and tumor necrosis factor-alpha act together to induce the cellular inhibitor of apoptosis-2 gene and prevent apoptosis in a variety of cell types. Endocrinology 2002; 143:3866-74.
14. Yang Y, Fang S, Jensen JP, Weissman AM, Ashwell JD. Ubiquitin protein ligase activity of IAPs and their degradation in proteasomes in response to apoptotic stimuli. Science 2000; 288:874-7.
15. Yang Y, Mercep M, Ware CF, Ashwell JD. Fas and activation-induced Fas ligand mediate apoptosis of T cell hybridomas: Inhibition of Fas ligand expression by retinoic acid and glucocorticoids. J Exp Med 1995; 181:1673-82.
16. Yerramasetti R, Gollapudi S, Gupta S. Rifampicin inhibits CD95-mediated apoptosis of Jurkat T cells via glucocorticoid receptors by modifying the expression of molecules regulating apoptosis. J Clin Immunol 2002; 22:37-47.
17. Zipp F, Wendling U, Beyer M, Grieger U, Waiczies S, Wagenknecht B, Haas J, Weller M. Dual effect of glucocorticoids on apoptosis of human autoreactive and foreign antigen-specific T cells. J Neuroimmunol 2000; 110:214-22.
18. Topper YJ, Freeman CS. Multiple hormone interactions in the developmental biology of the mammary gland. Physiol Rev 1980; 60:1049-106.
19. Feng Z, Marti A, Jehn B, Altermatt HJ, Chicaiza G, Jaggi R. Glucocorticoid and progesterone inhibit involution and programmed cell death in the mouse mammary gland. J Cell Biol 1995; 131:1095-103.
20. Lund LR, Romer J, Thomasset N, Solberg H, Pyke C, Bissell MJ, Dano K, Werb Z. Two distinct phases of apoptosis in mammary gland involution: Proteinase-independent and -dependent pathways. Development 1996; 122:181-93.
21. Moran TJ, Gray S, Mikosz CA, Conzen SD. The glucocorticoid receptor mediates a survival signal in human mammary epithelial cells. Cancer Res 2000; 60:867-72.
22. Furth PA. Introduction: Mammary gland involution and apoptosis of mammary epithelial cells. J Mammary Gland Biol Neoplasia 1999; 4:123-7.
23. Mikosz CA, Brickley DR, Sharkey MS, Moran TW, Conzen SD. Glucocorticoid receptor-mediated protection from apoptosis is associated with induction of the serine/threonine survival kinase gene, sgk-1. J Biol Chem 2001; 276:16649-54.
24. Wu W, Chaudhuri S, Brickley DR, Pang D, Karrison T, Conzen SD. Microarray analysis reveals glucocorticoid-regulated survival genes that are associated with inhibition of apoptosis in breast epithelial cells. Cancer Res 2004; 64:1757-64.
25. Engelbrecht Y, de Wet H, Horsch K, Langeveldt CR, Hough FS, Hulley PA. Glucocorticoids induce rapid upregulation of mitogen-activated protein kinase phosphatase-1 and dephosphorylation of extracellular signal-regulated kinase and impair proliferation in human and mouse osteoblast cell lines. Endocrinology 2003; 144:412-22.
26. Kobayashi T, Cohen P. Activation of serum- and glucocorticoid-regulated protein kinase by agonists that activate phosphatidylinositide 3-kinase is mediated by 3-phosphoinositidedependent protein kinase-1 (PDK1) and PDK2. Biochem J 1999; 339:319-28.
27. Leong ML, Maiyar AC, Kim B, O'Keeffe BA, Firestone GL. Expression of the serum- and glucocorticoid-inducible protein kinase, Sgk, is a cell survival response to multiple types of environmental stress stimuli in mammary epithelial cells. J Biol Chem 2003; 278:5871-82.
28. Wu W, Pew T, Zou M, Pang D, Conzen SD. Glucocorticoid receptor-induced MAPK phosphatase-1 (MPK-1) expression inhibits paclitaxel-associated MAPK activation and contributes to breast cancer cell survival. J Biol Chem 2005; 280:4117-24.
29. Loda M, Capodieci P, Mishra R, Yao H, Corless C, Grigioni W, Wang Y, Magi-Galluzzi C, Stork PJ. Expression of mitogen-activated protein kinase phosphatase-1 in the early phases of human epithelial carcinogenesis. Am J Pathol 1996; 149:1553-64.
30. Magi-Galluzzi C, Mishra R, Fiorentino M, Montironi R, Yao H, Capodieci P, Wishnow K, Kaplan I, Stork PJ, Loda M. Mitogen-activated protein kinase phosphatase 1 is overexpressed in prostate cancers and is inversely related to apoptosis. Lab Invest 1997; 76:37-51.
31. Srikanth S, Franklin CC, Duke RC, Kraft RS. Human DU145 prostate cancer cells overexpressing mitogen-activated protein kinase phosphatase-1 are resistant to Fas ligand-induced mitochondrial perturbations and cellular apoptosis. Mol Cell Biochem 1999; 199:169-78.
32. Steinmetz R, Wagoner HA, Zeng P, Hammond JR, Hannon TS, Meyers JL, Pescovitz OH. Mechanisms regulating the constitutive activation of the extracellular signal-regulated kinase (ERK) signaling pathway in ovarian cancer and the effect of ribonucleic acid interference for ERK1/2 on cancer cell proliferation. Mol Endocrinol 2004; 18:2570-82.
33. Campora E, Giudici S, Merlini L, Rubagotti A, Rosso R. Ondansetron and dexamethasone versus standard combination antiemetic therapy. A randomized trial for the prevention of acute and delayed emesis induced by cyclophosphamide- doxorubicin chemotherapy and maintenance of antiemetic effect at subsequent courses. Am J Clin Oncol 1994; 17:522-6.
34. Munstedt K, Borces D, Bohlmann MK, Zygmunt M, von Georgi R. Glucocorticoid administration in antiemetic therapy: Is it safe? Cancer 2004; 101:1696-702.
35. Mariotta M, Perewusnyk G, Koechli OR, Little JB, von Knebel Doeberitz M, Mirimanoff RO, Rutz HP. Dexamethasone-induced enhancement of resistance to ionizing radiation and chemotherapeutic agents in human tumor cells. Strahlenther Onkol 1999; 175:392-6.
36. Herr I, Ucur E, Herzer K, Okouoyo S, Ridder R, Krammer PH, von Knebel Doeberitz M, Debatin KM. Glucocorticoid cotreatment induces apoptosis resistance toward cancer therapy in carcinomas. Cancer Res 2003; 63:3112-20.
37. Innocenti F, Danesi R, Di Paolo A, Agen C, Nardini D, Bocci G, Del Tacca M. Plasma and tissue disposition of paclitaxel (taxol) after intraperitoneal administration in mice. Drug Metab Dispos 1995; 23:713-7.
38. Anderson CD, Wang J, Kumar GN, McMillan JM, Walle UK, Walle T. Dexamethasone induction of taxol metabolism in the rat. Drug Metab Dispos 1995; 23:1286-90.
39. Busse D, Busch FW, Bohnenstengel F, Eichelbaum M, Fischer P, Opalinska J, Schumacher K, Schweizer E, Kroemer HK. Dose escalation of cyclophosphamide in patients with breast cancer: Consequences for pharmacokinetics and metabolism. J Clin Oncol 1997; 15:1885-96.
40. Kishi S, Yang W, Boureau B, Morand S, Das S, Chen P, Cook EH, Rosner GL, Schuetz E, Pui CH, Relling MV. Effects of prednisone and genetic polymorphisms on etoposide disposition in children with acute lymphoblastic leukemia. Blood 2004; 103:67-72.
41. Jang SH, Wientjes MG, Au JL. Enhancement of paclitaxel delivery to solid tumors by apoptosis-inducing pretreatment: Effect of treatment schedule. J Pharmacol Exp Ther 2001; 296:1035-42.
42. Milas L, Hunter NR, Kurdoglu B, Mason KA, Meyn RE, Stephens LC, Peters LJ. Kinetics of mitotic arrest and apoptosis in murine mammary and ovarian tumors treated with taxol. Cancer Chemother Pharmacol 1995; 35:297-303.
43. Gown AM, Willingham MC. Improved detection of apoptotic cells in archival paraffin sections: Immunohistochemistry using antibodies to cleaved caspase 3. J Histochem Cytochem 2002; 50:449-54.
44. Oh HY, Namkoong S, Lee SJ, Por E, Kim CK, Billiar TR, Han JA, Ha KS, Chung HT, Kwon YG, Lee H, Kim YM. Dexamethasone protects primary cultured hepatocytes from death receptor-mediated apoptosis by upregulation of cFLIP. Cell Death Differ 2006; 13:512-23.
45. Webster MK, Goya L, Ge Y, Maiyar AC, Firestone GL. Characterization of sgk, a novel member of the serine/threonine protein kinase gene family which is transcriptionally induced by glucocorticoids and serum. Mol Cell Biol 1993; 13:2031-40.
46. Murata S, Yoshiara T, Lim CR, Sugino M, Kogure M, Ohnuki T, Komurasaki T, Matsubara K. Psychophysiological stress-regulated gene expression in mice. FEBS Lett 2005; 579:2137-42.
47. Brennan FE, Fuller PJ. Rapid upregulation of serum and glucocorticoid-regulated kinase (sgk) gene expression by corticosteroids in vivo. Mol Cell Endocrinol 2000; 166:129-36.
48. Bacus SS, Gudkov AV, Lowe M, Lyass L, Yung Y, Komarov AP, Keyomarsi K, Yarden Y, Seger R. Taxol-induced apoptosis depends on MAP kinase pathways (ERK and p38) and is independent of p53. Oncogene 2001; 20:147-55.
49. Ghaffari S, Jagani Z, Kitidis C, Lodish HF, Khosravi-Far R. Cytokines and BCR-ABL mediate suppression of TRAIL-induced apoptosis through inhibition of forkhead FOXO3a transcription factor. Proc Natl Acad Sci USA 2003; 100:6523-8.
50. Modur V, Nagarajan R, Evers BM, Milbrandt J. FOXO proteins regulate tumor necrosis factor-related apoptosis inducing ligand expression. Implications for PTEN mutation in prostate cancer. J Biol Chem 2002; 277:47928-37.
51. Brunet A, Park J, Tran H, Hu LS, Hemmings BA, Greenberg ME. Protein kinase SGK mediates survival signals by phosphorylating the forkhead transcription factor FKHRL1 (FOXO3a). Mol Cell Biol 2001; 21:952-65.
52. Bhattacharjee RN, Banks GC, Trotter KW, Lee HL, Archer TK. Histone H1 phosphorylation by Cdk2 selectively modulates mouse mammary tumor virus transcription through chromatin remodeling. Mol Cell Biol 2001; 21:5417-25.
53. Hershberger PA, Modzelewski RA, Shurin ZR, Rueger RM, Trump DL, Johnson CS. 1,25-Dihydroxycholecalciferol (1,25-D3) inhibits the growth of squamous cell carcinoma and downmodulates p21(Waf1/Cip1) in vitro and in vivo. Cancer Res 1999; 59:2644-9.
54. Iversen HG, Hjort GH. The influence of corticoid steroids on the frequency of spleen metastases in patients with breast cancer. Acta Pathol Microbiol Scand 1958; 44:205-12.
55. Sherlock P, Hartmann WH. Adrenal steroids and the pattern of metastases of breast cancer. Jama 1962; 181:313-7.
56. Tsuei SE, Moore RG, Ashley JJ, McBride WG. Disposition of synethetic glucocorticoids. I. Pharmacokinetics of dexamethasone in healthy adults. J Pharmacokinet Biopharm 1979; 7:249-64.
57. Brady ME, Sartiano GP, Rosenblum SL, Zaglama NE, Bauguess CT. The pharmacokinetics of single high doses of dexamethasone in cancer patients. Eur J Clin Pharmacol 1987; 32:593-6.
58. Chang TK, Yu L, Maurel P, Waxman DJ. Enhanced cyclophosphamide and ifosfamide activation in primary human hepatocyte cultures: Response to cytochrome P-450 inducers and autoinduction by oxazaphosphorines. Cancer Res 1997; 57:1946-54.
59. Jamis-Dow CA, Klecker RW, Katki AG, Collins JM. Metabolism of taxol by human and rat liver in vitro: A screen for drug interactions and interspecies differences. Cancer Chemother Pharmacol 1995; 36:107-14.
60. Sui M, Chen F, Chen Z, Fan W. Glucocorticoids interfere with therapeutic efficacy of paclitaxel against human breast and ovarian xenograft tumors. Int J Cancer 2006; In press.